Presenting the ClearCell® FX System

Label-free CTC Enrichment for Real-time Insights


Cancer treatment is fraught with uncertainty, both for you and your patients. Now there is a faster, more elegant solution for cell enrichment—ClearCell® FX. Fully automated and entirely label-free, ClearCell® FX empowers doctors through every step of the cancer treatment journey.

Based on the patented microfluidic biochip, CTChip® FR, ClearCell® FX achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring. Clinicians now have a robust and reproducible non-invasive liquid biopsy to monitor metastasis—bringing us closer to providing timely, tailored treatment for patients.


  • Label-free CTC enrichment of heterogeneous populations of cancer cells
  • Up to 10,000x enrichment of CTCs
  • Large blood volume enrichment from 7.5ml of patients’ blood
  • Fast processing time of less than an hour
  • Automated workflow
  • Sensitive, with a high dynamic range
  • Easy and ready integration with a wide variety of downstream molecular diagnostics and pathology assays
  • CE marked and ISO 13485 certified, verifying comprehensive quality management
Learn more about the ClearCell FX here


See our system at ASCO 2014, Chicago, May 30th – June 2nd. Booth no. 5048

Download our Clearcell®FX launch press release here



Fluorescence In Situ Hybridisation (FISH)

EML4-ALK gene rearrangement in a non-small cell lung cancer (NSCLC) CTC that had been isolated with the ClearCell® FX System and analysed by FISH. Image courtesy of National Cancer Centre, Singapore

Cell Culture

MCF7 breast cancer cells in culture after isolation using the CTChip® FR1

Molecular Analysis

Detection of a KRAS mutation in a CTC- enriched sample that had been isolated using the ClearCell® FX System and analysed by Sanger sequencing

Immunofluorescence (IF) / Immunocytochemistry (ICC)

DAPI (in blue), pan-cytokeratin (CK) (in green) and CD45 (in red) staining of cells isolated using the ClearCell® FX System. CTCs are shown to be CK + and CD45

Click the above images to download application note


Clearbridge BioMedics specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) and is the first incubatee of Clearbridge Accelerator,a high-technology incubator backed by the Singapore Government’s National Research Foundation.

The ClearCell Systems provide a label-free means of Circulating Tumour Cell (CTC) enrichment, as such, offering a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.





Contact Us

For enquiries on distribution and our Early Access Program for the ClearCell® FX System,
please send us a message!

 The Chadwick, 81 Science Park Drive #02-03, Singapore 118257

+65 6873 0668
 +65 6873 0778

Send a Message